Contemporary Microbiological Diagnostic Tests for Rapid

Identification and Detection of Resistance of Mycobacterium tuberculosis



Faculty of Medical Sciences, Univ. "Goce Delchev" Sthip, Republic of Macedonia Presenter's phone 389 78 604 932, e-mail: oliver.111672@student.ugd.edu.mk

INTRODUCTION

- Tuberculosis (TB) occurs in every part of the world as a top infectious disease killer.
- In 2014, 9.6 million cases (an estimated 1 million children) and 1.5 million deaths (140 000 children) from TB were registered. Over 95% of TB deaths occur in developing countries.
- TB incidence has fallen since 2000 and is now 18% lower, by an average of 1.5% per year.

MATERIAL and METHODS

- Material and methods in use in National reference laboratory of Republic of Macedonia (microbiological laboratory at the Institute for lung diseases).
- Standard methods in use:
- Ziehl Neelsen staining/ or Cold staining- Kinyon method
- Antitubreculotic drugs susceptibility testing on modified Lövenstein-Jensen medium for:
- Isoniazid (H) 0,2 μg/l
- Rifampicin ® 40,0 μg/l
- Ethambutol (E) 2,0 μg/l
- Streptomycin (S) 4,0 µg/l

- TB is a treatable and curable disease with a standard 6 month protocol of 4 antimicrobial drugs. In cases of multi-drug resistant TB (MDR-TB) responds are very week including the most effective second-line anti-TB drugs. About 480 000 people developed MDR-TB in the world in 2014.
- Standard anti-TB drugs have been used for decades, and resistance to a single anti-TB drug have been documented in every country worldwide.
- Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond to, at least, isoniazid and rifampicin, the 2 most powerful, first-line (or standard) anti-TB drugs.

Contemporary methods:

Bactec MGIT 960

Is an automated method enable identification of Mycobacterium tuberculosis for 4-12 -20 days, and susceptibility testing on: streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide, and tests for antituberculosis drug of second line.





Bactec MGIT 960


International symposium at Faculty of medical sciences CURRENT ACHIEVEMENTS AND FUTURE PERSPECTIVES IN MEDICAL AND BIOMEDICAL RESEARCH STIP 24 NOVEMBER 2015 MILITARENA CENTRE - LIGH STIP

OBJECTIVE

- To give overview on contemporary microbiological diagnostic tests for rapid identification and detection of resistance of Mycobacterium tuberculosis
- To present possibilities of microbiological diagnostic tests for identification and detection of resistance of Mycobacterium tuberculosis in National laboratory in Republic of Macedonia
- To present data of results of some methods for rapid identification and detection of resistance of Mycobacterium tuberculosis

GeneXpert

WHO monitoring Xpert MTB/RIF, managed by the WHO Global TB Program, is an automated, cartridge-based nucleic amplification assay for the simultaneous detection of TB and rifampicin resistance directly from sputum in under two hours. The technology is based on the GeneXpert platform





•	RI	ES	UL	TS

Year	2010	2011	2012	2013	2014
Positive	502	350	428	376	375
Negative	5339	5594	5519	6060	6061

Culture results on Lővenstein-Jensen medium

Year	2010	2011	2012	2013	2014	
Positive	ositive 52		86	77	?	
Negative	335	433	569	835	?	

Bactec MGIT 960 results

Year	2009	2010	2011	2012	2013	2014
TB strains	191(100%)	181(100%)	155(100%)	181(100%)	198(100%)	154(100)
Sensitive	175(91,6%)	170(93,9%)	143(92,2%)	163(90%)	191(96,4%)	142(92,%)
Resistant	16 (8,3%)	11 (6%)	12 (7,7%)	18 (10%)	7 (3,5%)	12 (7,5%)
Mono-resistant	14 (7,3%)	3 (1,6%)	9 (5,8%)	11 (6%)	6 (3%)	10 (5,8%)
Rifampicin resistant	3 (1,5%)	1	5 (3,2%)	1 (0,5%)	1 (0,5%)	3 (1,7%)
MDR	1 (0,5%)	7 (3,8%)	1 (0,6%)	4(2,2%)	1 (0,5%)	2 (1,2%)

TB resistance over period 2009 - 2014

CONCLUSIONS

- In National reference laboratory for Identification and Detection of Resistance of *Mycobacterium tuberculosis*, beside standard Methods, contemporary rapid methods recommended by WHO Experts and Global TB Program, such are: Bactec MGIT and GeneXpert are priority.
- Rapid methods enable final diagnosis of TB, including isolation, identification and susceptibility testing in significantly shorter time.
- Number of new TB infections in Republic of Macedonia is decreasing continuously in past 10 years.
- MDR strains in Republic of Macedonia are at low level.









WHO Goal target is ending the TB epidemic by 2030